Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASTRO In Brief

This article was originally published in The Gray Sheet

Executive Summary

Proton therapy for prostate cancer: Three prospective studies show that radiation with proton beam therapy in prostate cancer patients causes minimal urinary and rectal side effects, according to a Nov. 2 presentation by Nancy Mendenhall, M.D., University of Florida Proton Therapy Institute, at the American Society for Radiation Oncology annual meeting in Chicago. Investigators examined genitourinary and gastrointestinal toxicity scores in 212 proton therapy patients one year post-treatment. Results showed that less than 1% of patients had severe Grade 3 genitourinary side effects and less than one-half percent experienced Grade 3 GI toxicities. In a separate presentation, Carl J. Rossi, M.D., et al., Loma Linda University Medical Center, showed data from a randomized trial concluding men who receive a "boost" of proton therapy after receiving standard X-ray radiation therapy have fewer recurrences of prostate cancer

You may also be interested in...



New Philadelphia Proton Therapy Center Promises Heavy Research Focus

Protons will one day overtake photons as the dominant cancer radiation tool, and research conducted at the new Roberts Proton Therapy Center in Philadelphia will help accelerate the technology's adoption, contends Zelig Tochner, medical director of the facility

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.

Topics

UsernamePublicRestriction

Register

MT028127

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel